HUMIRA BIOSIMILAR MARKET ANALYSIS

Regional Analysis

North America: The North American market, particularly the U.S., has been a significant player in the humira biosimilar market. However, the introduction of biosimilars in this region faced challenges due to patent protections and complex regulatory processes. With the expiration of humira's patents, the market for biosimilars is expected to grow in North America. North America holds a substantial percentage of the market share, accounting for approximately 45.2%.

Europe: Europe has been at the forefront of biosimilar adoption and witnessed the approval and launch of several humira biosimilars in its market. The region established regulatory pathways and policies that support the uptake of biosimilars, leading to increased market competition and potential cost savings. Europe holds around 30.7% of the market share, highlighting its significance in the humira biosimilar market.

Asia Pacific: The Asia Pacific region, including countries like Japan, South Korea, and Australia, witnessed the emergence of humira biosimilars. Factors such as the increasing prevalence of autoimmune diseases and the need for more affordable treatment options have driven the market in this region. However, regulatory approvals and market access for biosimilars vary across countries within the Asia Pacific region. Asia-Pacific accounts for approximately 16.8% of the market share.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East & Africa:  GCC Countries, Israel,  South Africa, North Africa, Central Africa, and Rest of Middle East